ATHENA: A Phase 3, Open-Label Study Of The Safety And Effectiveness Of Oliceridine (TRV130), A G-Protein Selective Agonist At The µ-Opioid Receptor, In Patients With Moderate To Severe Acute Pain Requiring Parenteral Opioid Therapy

BACKGROUND: Pain management with conventional opioids can be challenging due to dose-limiting adverse events (AEs), some of which may be related to the simultaneous activation of β-arrestin (a signaling pathway associated with opioid-related AEs) and G-protein pathways. The investigational analgesic...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Pain Res
Autori principali: Bergese, Sergio D, Brzezinski, Marek, Hammer, Gregory B, Beard, Timothy L, Pan, Peter H, Mace, Sharon E, Berkowitz, Richard D, Cochrane, Kristina, Wase, Linda, Minkowitz, Harold S, Habib, Ashraf S
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove 2019
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6861532/
https://ncbi.nlm.nih.gov/pubmed/31814753
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JPR.S217563
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi